United Therapeutics Corp (UTHR) Stock Price & Analysis
United Therapeutics Corp (UTHR) rose 1.55% to USD 553.14 as of June 10, 2026 at 00:46 UTC, according to Nexqual real-time market data.
UTHR last closed at USD 544.69; the session ranged USD 544–554.48 on volume of 325,571 shares. Market capitalization is $23.48B, with a 52-week range of USD 272.12–609.35 (NMS). Source: Nexqual, June 10, 2026 at 00:46 UTC.
Key Statistics (as of June 10, 2026 at 00:46 UTC)
| Price | USD 553.14 |
|---|---|
| Change | ▲ 1.55% (up) |
| Previous Close | USD 544.69 |
| Open | USD 550.89 |
| Day Range | USD 544 – 554.48 |
| 52-Week Range | USD 272.12 – 609.35 |
| Volume | 325,571 shares |
| Market Cap | $23.48B |
| Exchange | NMS |
Technical Analysis (UTHR)
Nexqual's technical model rates UTHR "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:46 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 44.82 (neutral) |
| vs SMA50 | Below (USD 569.44) |
| MACD | -5.59 (negative) |
Analyst Ratings (UTHR)
Wall Street analysts rate UTHR "Buy" based on 13 analysts, with a mean price target of USD 665.23 (range USD 516–750), per Nexqual as of June 10, 2026 at 00:46 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 665.23 |
| High Target | USD 750 |
| Low Target | USD 516 |
| Buy / Hold / Sell | 12 / 3 / 0 |
Earnings (UTHR)
| Next Earnings Date | 2026-07-29 |
|---|---|
| EPS Estimate | USD 6.92 |
| Revenue Estimate | $810.42M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 5.82 vs est 6.86 ▼ miss |
| 2025-12-31 | USD 7.7 vs est 6.76 ▲ beat |
| 2025-09-30 | USD 7.16 vs est 6.96 ▲ beat |
| 2025-06-30 | USD 6.41 vs est 6.94 ▼ miss |
Source: Nexqual, June 10, 2026 at 00:46 UTC.
Financials & Fundamentals (UTHR)
| Total Revenue | $3.17B |
|---|---|
| Revenue Growth (YoY) | -1.60% |
| Gross Margin | +86.58% |
| Operating Margin | +41.69% |
| Profit Margin | +40.62% |
| ROE | +20.26% |
| Current Ratio | 4.79 |
| Total Cash | $2.15B |
| Total Debt | $0 |
| Free Cash Flow | $566.41M |
Source: Nexqual, June 10, 2026 at 00:46 UTC.
Financial Health Score (UTHR)
Nexqual rates United Therapeutics Corp's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 00:46 UTC.
| Growth | Solid — Revenue +11% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 87%, operating 42% |
| Balance Sheet | Mixed — $2.15B cash, no debt |
| Cash Flow | Strong — FCF $566M, 18% margin |
| Efficiency | Strong — ROE 20%, ROA 12.6% |
Ownership (UTHR)
| Insider Ownership | +2.04% |
|---|---|
| Institutional Ownership | +102.13% |
| Shares Outstanding | 42.45M |
| Float | 38.92M |
| Short % of Float | +6.04% |
Source: Nexqual, June 10, 2026 at 00:46 UTC.
Leadership (UTHR)
United Therapeutics Corp is led by Martine A. Rothblatt J.D. (age 70), Founder, Chairman & CEO, per Nexqual as of June 10, 2026 at 00:46 UTC.
| Founder, Chairman & CEO | Martine A. Rothblatt J.D. (age 70) |
|---|---|
| President & COO | Michael I. Benkowitz (age 53) |
| CFO & Treasurer | James C. Edgemond (age 57) |
| Associate Vice President of Human Resources | Holly Hobson |
| Executive Vice President of Product Development & Xenotransplantation | Leigh Peterson |
Major Backers & Investors (UTHR)
Notable institutional backers of United Therapeutics Corp include Avoro Capital Advisors LLC, Wellington Management, Renaissance Technologies, according to Nexqual as of June 10, 2026 at 00:46 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Avoro Capital Advisors LLC | 6.2% |
| Wellington Management | 5.33% |
| Renaissance Technologies | 4.21% |
| Janus Henderson Group PLC | 2.04% |
| AQR Capital Management, LLC | 1.95% |
| Invesco | 0.85% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 19.74% |
| BlackRock | 17.51% |
| State Street | 5.11% |
| Geode Capital | 2.9% |
Source: Nexqual, June 10, 2026 at 00:46 UTC.
From United Therapeutics Corp's Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Nebulized Tyvaso is administered four times a day using our proprietary Tyvaso Inhalation System, which consists of an ultrasonic nebulizer and related accessories.
- Nebulized Tyvaso is regulated by the FDA as a drug-device combination product approved under an NDA consisting of Tyvaso drug product and the Tyvaso Inhalation System.
- Ex Vivo Lung Perfusion Our ex vivo lung perfusion ( EVLP ) program uses the first FDA-approved acellular EVLP technology on the market, the XVIVO Perfusion System ( XPS ™) with Steen Solution™ Perfusate, to offer the only commercially-available centralized EVLP service in the United States.
- In 2024, Lung Bioengineering completed a registrational study of another centralized EVLP technology called the Centralized Lung Evaluation System ( CLES ) and submitted a premarket approval application to the FDA in September 2024 for commercial approval of CLES, which is under review by the FDA.
Partnerships
- Under our agreement with 3D Systems, we also have the exclusive right to develop additional human solid organ alternatives using 3D Systems' printing technology. • IVIVA .
- Remunity and RemunityPRO Pumps In February 2021, we launched commercial sales of the Remunity Pump, which is a semi-disposable system for subcutaneous delivery of treprostinil that we developed in collaboration with DEKA Research & Development Corp. ( DEKA ) under an exclusive development and license agreement.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NBIX | Neurocrine Biosciences, Inc. | USD 165.24 | ▲ 0.83% |
| BMRN | BioMarin Pharmaceutical Inc. | USD 57.91 | ▲ 2.01% |
| JAZZ | Jazz Pharmaceuticals plc | USD 229.19 | ▼ 3.93% |
| ALNY | Alnylam Pharmaceuticals, Inc. | USD 297.69 | ▼ 1.77% |
| TECH | Bio-Techne Corp | USD 54.41 | ▲ 4.65% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:46 UTC. This page is informational and not investment advice.